VANCOUVER, Sept. 13 -- CNW/ AsiaNet
ARC Pharmaceuticals Inc. announced today that Dr. Johanne Cashman, Director
of Preclinical of Research, published a paper entitled "Camptothecin-loaded
Films for the Prevention of Postsurgical Adhesions" in the August 2004 issue of
Inflammation Research.
"The publication is a significant recognition for ARC," stated Dr.
Cashman. "This international journal provides an excellent peer-reviewed forum
to showcase the novel research we are conducting at ARC in the development of
innovative medical therapies for the prevention and treatment of postsurgical
adhesions."
Adhesion disease causes dysfunction and pain in millions of patients
worldwide and is a major complication in a high proportion of common surgical
procedures. It is a complex inflammatory disorder in which tissues that
normally remain separated in the body grow into each other, usually as a
response of the tissues to surgical trauma. Dr. Cashman's paper examines the
local application of camptothecin, a drug with anti-inflammatory and anti-
proliferative properties, as an inhibitor of postsurgical adhesion formation
in rats.
Although there are products currently marketed for the prevention of
surgical adhesion disease such as films, gels and sprays, these act by only
physically separating tissues, and do not affect the underlying inflammatory
processes that are responsible for the formation of postsurgical adhesions.
Dr. Cashman's investigation concluded that camptothecin-loaded polymeric films
significantly reduced the number, severity and extent of adhesions in the rat
cecal sidewall model of surgical adhesion disease.
Dr. Cashman's research strongly supports ARC's product development
strategy of incorporating anti-inflammatory drugs into polymeric barriers for
the prevention and treatment of postsurgical adhesions.
To view a copy of Dr. Cashman's research paper, please visit
www.arcpharma.com/_resources/Cashman_InflamRes_2004.pdf or www.birkhauser.ch.
About ARC Pharmaceuticals Inc.:
ARC is a private biotechnology company focused on the development and
commercialization of device/drug therapies for the treatment of proliferative
diseases. The Company's lead product candidates are innovative medical
products for the treatment of surgical adhesions.
This report may contain certain forward-looking information and
statements concerning the Company's operation, performance and financial
condition, including, in particular, the likelihood of securing licenses or
other intellectual property for drug delivery systems and therapeutics for the
treatment of inflammatory and proliferative diseases, the likelihood of the
completion of the development of new clinical products for the treatment of
inflammatory and proliferative diseases, and the likelihood of completing
financings. These statements are based upon a number of uncertainties and
contingencies, many of which are beyond the control of the Company. Actual
results may differ materially from those expressed or implied by such forward-
looking statements. This document is not intended to be and is not an
advertisement for any securities of the Company.
Source: ARC Pharmaceuticals Inc.
Contact: Amanda Smith,
Corporate Communications,
102-2386 East Mall, Vancouver, BC, V6T 1Z3,
Phone (604) 626-6264,
Email: [email protected]
Web: www.arcpharma.com
--Distributed by AsiaNet (www.asianetnews.net)--
--InfoQuest (PP)--